Compare CHR & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | APVO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.3M |
| IPO Year | 2018 | 2023 |
| Metric | CHR | APVO |
|---|---|---|
| Price | $1.52 | $1.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.0K | 40.9K |
| Earning Date | 07-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | $105.44 | N/A |
| Revenue Next Year | $30.02 | N/A |
| P/E Ratio | $25.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.53 |
| 52 Week High | $2.95 | $10.70 |
| Indicator | CHR | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 39.69 |
| Support Level | $1.51 | $1.71 |
| Resistance Level | $1.69 | $1.98 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 14.29 | 39.13 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.